Alnylam Pharmaceuticals | ALNY - Stammkapital

Aktienkurs
309.49
Täglich Wechseln
8.30 2.76%
Monatlich
-6.46%
Jährlich
21.31%
Q2 Prognose
299.00




Stammkapital Veränderung Datum
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amgen USD 539M 1000K 2025-12
Arrowhead Research USD 135.7M 2.44M 2025-09
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Incyte USD 199.95M 1.49M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.91B 10.64M 2025-12
PTC Therapeutics USD 81.47M 1.54M 2025-12
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 104.96M 196K 2025-12
Takeda JPY 1.58B 2K 2025-12
Tectonic Therapeutic USD 18.74M 25.03K 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
Vertex Pharmaceuticals USD 254M 0 2025-12
Xencor USD 71.87M 529K 2025-12